ArticleClinical parkinsonism & related disorders2025
ACTB-associated dystonia-deafness syndrome with good response to DBS GPi revisited.
Article in Clinical parkinsonism & related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dystonia-deafness syndrome is a rare disorder characterized by dystonia with sensorineural hearing impairment. While various genetic causes have been identified, many cases remain unexplained. Deep brain stimulation of the globus pallidus internus is an established treatment for dystonia, but outcomes vary depending on the underlying cause. Methods: We conducted a long-term follow-up of a 31-year-old male diagnosed with DDS, initially reported in 2016. Results: The patient exhibited progressive generalized dystonia and sensorineural hearing loss. At the age of 19, bilateral DBS-GPi implantation was performed, resulting in sustained symptom improvement until the age of 25. However, progressive worsening of dystonia led to the initiation of adjunctive botulinum toxin therapy, which initially provided symptom relief. At the age of 26, disruption of a DBS extension wire caused acute symptom exacerbation, necessitating surgical replacement. Further clinical deterioration was exacerbated by a hardware-related infection, leading to surgical removal of the left DBS system at the age of 30, which prompted placement of a percutaneous endoscopic gastrostomy. At the age of 31, the right-sided DBS system was also removed. Bilateral reimplantation of the DBS-GPi system was performed at the age of 31. Trio exome sequencing identified a Conclusion: This case highlights both the benefits and limitations of DBS in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.